Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy

Molecular Cancer Therapeutics

Volumn 12, Issue 8, 2013, Pages 1442-1452

  Guertin, Amy D ^a   Li, Jing ^c   Liu, Yaping ^c   Hurd, Melissa S ^b   Schuller, Alwin G ^b   Long, Brian ^b   Hirsch, Heather A ^c   Feldman, Igor ^c   Benita, Yair ^c   Toniatti, Carlo ^a,d   Zawel, Leigh ^a   Fawell, Stephen E ^a,e   Gilliland, D Gary ^a   Shumway, Stuart D ^a,c  

^a Oncology Biology   (United States)

^b In vivo Pharmacology ^*  (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DNA; DOXORUBICIN; MEMBRANE PROTEIN; MK 1775; MK 775; PKMYT1 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SYNCHRONIZATION; CONTROLLED STUDY; DNA DAMAGE; DNA REPLICATION; DOUBLE STRANDED DNA BREAK; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; FLOW CYTOMETRY; GROWTH INHIBITION; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DNA DAMAGE; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MEMBRANE PROTEINS; MICE; NEOPLASMS; NUCLEAR PROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84882253419     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0025     Document Type: Article

References (43)

1. Medema RH, Macurek L. Checkpoint control and cancer. Oncogene 2012;31:2601-13.
2. Parker LL, Piwnicaworms H. Inactivation of the P34(Cdc2)-cyclin-B complex by the human WEE1 tyrosine kinase. Science 1992;257: 1955-7.
3. Watanabe N, Broome M, Hunter T. Regulation of the human WEE1Hu Cdk tyrosine 15-kinase during the cell-cycle. EMBO J 1995;14: 1878-91.
4. Hamer PCD, Mir SE, Noske D, Van Noorden CJF, Wurdinger T. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. Clin Cancer Res 2011;17:4200-7.
5. Mcgowan CH, Russell P. Human WEE1 kinase inhibits cell-division by phosphorylating P34(Cdc2) exclusively on Tyr15. EMBO J 1993;12: 75-85.
6. Tominaga Y, Li C, Wang R-H, Deng C-X. Murine WEE1 plays a critical role in cell cycle regulation and pre-implantation stages of embryonic development. Int J Biol Sci 2006;2:161-70.
7. Beck H, Nahse V, Larsen MSY, Groth P, Clancy T, Lees M, et al. Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase. J Cell Biol 2010;188:629-38.
8. Dominguez-Kelly R, Martin Y, Koundrioukoff S, Tanenbaum ME, Smits VAJ, Medema RH, et al. WEE1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease. J Cell Biol 2011;194:567-79.
9. Beck H, Nahse-Kumpf V, Larsen MS, O'Hanlon KA, Patzke S, Holmberg C, et al. Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption. Mol Cell Biol 2012;32:4226-36.
10. Mir SE, Hamer PCD, Krawczyk PM, Balaj L, Claes A, Niers JM, et al. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell 2010;18: 244-57.
11. Magnussen GI, Holm R, Emilsen E, Rosnes AKR, Slipicevic A, Florenes VA. High expression of WEE1 is associated with poor disease-free survival in malignant melanoma: Potential for targeted therapy. PLoS One 2012;7:e38254.
12. Masaki T, Shiratori Y, Rengifo W, Igarashi K, Yamagata M, Kurokohchi K, et al. Cyclins and cyclin-dependent kinases: Comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology 2003;37: 534-43.
13. Iorns E, Lord CJ, Grigoriadis A, McDonald S, Fenwick K, Mackay A, et al. Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS One 2009;4:e5120.
14. Backert S, Gelos M, Kobalz U, Hanski ML, Bohm C, Mann B, et al. Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array. Int J Cancer 1999;82:868-74.
15. Yoshida T, Tanaka S, Mogi A, Shitara Y, Kuwano H. The clinical significance of Cyclin B1 and WEE1 expression in non-small-cell lung cancer. Ann Oncol 2004;15:252-6.
16. Wu ZX, Doondeea JB, Gholami AM, Janning MC, Lemeer S, Kramer K, et al. Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer. Mol Cell Proteomics 2011;10: M111.011635.
17. Sorensen CS, Syljuasen RG. Safeguarding genome integrity: The checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication. Nucleic Acids Res 2012;40:477-86.
18. Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, et al. Small-molecule inhibition of WEE1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 2009;8:2992-3000.
19. Stathis A, Oza A. Targeting WEE1-like protein kinase to treat cancer. Drug News Perspect 2010;23:425-9.
20. Schellens JHM, Shapiro G, Pavlick AC, Tibes R, Leijen S, Tolaney SM, et al. Update on a phase I pharmacologic and pharmacodynamic study of MK-1775, a WEE1 tyrosine kinase inhibitor, in monotherapy and combinationwith gemcitabine, cisplatin, or carboplatin in patientswith advanced solid tumors (2011 ASCO Annual Meeting). J Clin Oncol 29:2011, 2011 (suppl; abstr 3068).
21. Russell MR, Levin K, Rader J, Belcastro L, Li Y, Martinez D, et al. Combination therapy targeting the Chk1 and WEE1 kinases shows therapeutic efficacy in neuroblastoma. Cancer Res 2013;73:776-84.
22. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 2000;14:1448-59.
23. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA doublestranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998;273:5858-68.
24. Gurley LR, D'Anna JA, Barham SS, Deaven LL, Tobey RA. Histone phosphorylation and chromatin structure during mitosis in Chinese hamster cells. Eur J Biochem 1978;84:1-15.
25. Paulson JR, Taylor SS. Phosphorylation of histones 1 and 3 and nonhistone high mobility group 14 by an endogenous kinase in HeLa metaphase chromosomes. J Biol Chem 1982;257:6064-72.
26. Mueller PR, Coleman TR, Kumagai A, Dunphy WG. Myt1-A membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. Science 1995;270:86-90.
27. Broad Institute. Available from: Http://www.broadinstitute.org/ccle/home. Accessed May 2012.
28. Mizuarai S, Yamanaka K, Itadani H, Arai T, Nishibata T, Hirai H, et al. Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug WEE1 inhibitor. Mol Cancer 2009;8:34.
29. Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N, et al. MK-1775, a small molecule WEE1 inhibitor, enhances antitumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther 2010;9:514-22.
30. Aarts M, Sharpe R, Garcia-Murillas I, Gevensleben H, Hurd MS, Shumway SD, et al. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov 2012;2:524-39.
31. Indovina P, Giordano A. Targeting the checkpoint kinase WEE1 Selective sensitization of cancer cells to DNA-damaging drugs. Cancer Biol Ther 2010;9:523-5.
32. Wang YL, Decker SJ, Sebolt-Leopold J. Knockdown of Chk1, WEE1 and Myt1 by RNA interference abrogates G(2) checkpoint and induces apoptosis. Cancer Biol Ther 2004;3:305-13.
33. Murrow LM, Garimella SV, Jones TL, Caplen NJ, Lipkowitz S. Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome. Breast Cancer Res Treat 2010;122:347-57.
34. Kreahling JM, Gemmer JY, Reed D, Letson D, Bui M, Altiok S. MK1775, a selective WEE1 inhibitor, shows single-agent antitumor activity against sarcoma cells. Mol Cancer Ther 2012;11:174-82.
35. Martin Y, Dominguez-Kelly R, Freire R. Novel insights into maintaining genomic integrity: WEE1 regulating Mus81/Eme1. Cell Div 2011;6:21.
36. Tibes R, Bogenberger JM, Chaudhuri L, Hagelstrom RT, Chow D, Buechel ME, et al. RNAi screening of the kinome with cytarabine in leukemias. Blood 2012;119:2863-72.
37. El Touny LH, Banerjee PP. Identification of both Myt-1 and Wee-1 as necessary mediators of the p21-independent inactivation of the Cdc-2/cyclin B1 complex and growth inhibition of TRAMP cancer cells by genistein. Prostate 2006;66:1542-55.
38. Liu F, Rothblum-Oviatt C, Ryan CE, Piwnica-Worms H. Overproduction of human Myt1 kinase induces a G(2) cell cycle delay by interfering with the intracellular trafficking of Cdc2-cyclin B1 complexes. Mol Cell Biol 1999;19:5113-23.
39. Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T, et al. MK-1775, a potent WEE1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res 2011;17: 2799-806.
40. Davies KD, Cable PL, Garrus JE, Sullivan FX, von Carlowitz I, Huerou YL, et al. Chk1 inhibition and WEE1 inhibition combine synergistically to impede cellular proliferation. Cancer Biol Ther 2011;12:1-9.
41. Carrassa L, Chila R, Lupi M, Ricci F, Celenza C, Mazzoletti M, et al. Combined inhibition of Chk1 and WEE1 in vitro synergistic effect translates to tumor growth inhibition in vivo. Cell Cycle 2012;11: 2507-17.
42. Davies KD, Humphries MJ, Sullivan FX, von Carlowitz I, Le Huerou Y, Mohr PJ, et al. Single-agent inhibition of Chk1 is antiproliferative in human cancer cell lines in vitro and inhibits tumor xenograft growth in vivo. Oncol Res 2011;19:349-63.
43. Guertin AD, Martin MM, Roberts B, Hurd M, Qu X, Miselis NR, et al. Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition. Cancer Cell Int 2012;12:45.